Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited announced the issuance of 7.2 million ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX). This move is expected to enhance the company’s financial flexibility and support its strategic initiatives, thereby potentially strengthening its market position and providing value to its stakeholders.
More about Mesoblast Limited
Mesoblast Limited is a company operating in the biotechnology industry, primarily focused on the development and commercialization of innovative cellular medicines for inflammatory diseases, cardiovascular diseases, and back pain. The company targets global markets with its advanced therapies designed to improve patient outcomes.
YTD Price Performance: 140.91%
Average Trading Volume: 96,460
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.99B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.
